Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma
Cancers,
Год журнала:
2024,
Номер
16(17), С. 2975 - 2975
Опубликована: Авг. 27, 2024
Malignant
gliomas
present
great
difficulties
in
treatment,
with
little
change
over
the
past
30
years
median
survival
time
of
15
months.
Current
treatment
options
include
surgery,
radiotherapy
(RT),
and
chemotherapy.
New
therapies
aimed
at
suppressing
formation
new
vasculature
(antiangiogenic
treatments)
or
destroying
formed
tumor
(vascular
disrupting
agents)
show
promise.
This
study
summarizes
existing
knowledge
regarding
processes
by
which
glioblastoma
(GBM)
tumors
acquire
resistance
to
antiangiogenic
treatments.
The
discussion
encompasses
activation
redundant
proangiogenic
pathways,
heightened
cell
invasion
metastasis,
induced
hypoxia,
creation
vascular
mimicry
channels,
regulation
immune
microenvironment.
Subsequently,
we
explore
potential
strategies
overcome
this
resistance,
such
as
combining
other
methods,
personalizing
treatments
for
each
patient,
focusing
on
therapeutic
targets,
incorporating
immunotherapy,
utilizing
drug
delivery
systems
based
nanoparticles.
Additionally,
would
like
discuss
limitations
methods
future
directions
enhance
beneficial
effects
patients
GBM.
Therefore,
review
aims
research
outcome
GBM
provide
a
more
promising
opportunity
thoroughly
exploring
mechanisms
investigating
novel
strategies.
Язык: Английский
The Role of the Dysregulation of circRNAs Expression in Glioblastoma Multiforme
Journal of Molecular Neuroscience,
Год журнала:
2025,
Номер
75(1)
Опубликована: Янв. 22, 2025
Язык: Английский
The Clinical Role of miRNAs in the Development and Treatment of Glioblastoma
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(6), С. 2723 - 2723
Опубликована: Март 18, 2025
Glioblastoma
multiforme
(GBM)
is
the
most
common
brain
tumor
and
one
of
aggressive,
with
a
median
overall
survival
(OS)
only
15–18
months.
These
characteristics
make
it
necessary
to
identify
new
targets
for
improvement
prognosis
better
prediction
response
therapies
currently
available
GBM
patients.
One
possible
candidate
target
could
be
evaluation
miRNAs.
miRNAs
are
small
non-coding
RNAs
that
play
important
roles
in
post-transcriptional
gene
regulation.
Due
their
functions,
also
control
biological
processes
underlying
development
may
considered
clinical
role.
This
narrative
review
introduces
concept
from
molecular
perspective
then
addresses
specific
described
literature
as
relevant
development,
prognosis,
patients
affected
by
GBM.
Язык: Английский
Unraveling the noncoding RNA landscape in glioblastoma: from pathogenesis to precision therapeutics
K. Sandhanam,
Tamilanban Thamaraikani
Naunyn-Schmiedeberg s Archives of Pharmacology,
Год журнала:
2024,
Номер
397(12), С. 9475 - 9502
Опубликована: Июль 15, 2024
Язык: Английский
Mesenchymal-Stem-Cell-Based Therapy against Gliomas
Cells,
Год журнала:
2024,
Номер
13(7), С. 617 - 617
Опубликована: Апрель 2, 2024
Glioblastoma
is
the
most
aggressive,
malignant,
and
lethal
brain
tumor
of
central
nervous
system.
Its
poor
prognosis
lies
in
its
inefficient
response
to
currently
available
treatments
that
consist
surgical
resection,
radiotherapy,
chemotherapy.
Recently,
use
mesenchymal
stem
cells
(MSCs)
as
a
possible
kind
cell
therapy
against
glioblastoma
gaining
great
interest
due
their
immunomodulatory
properties,
tropism,
differentiation
into
other
types.
However,
MSCs
seem
present
both
antitumor
pro-tumor
properties
depending
on
tissue
from
which
they
come.
In
this
work,
possibility
using
deliver
therapeutic
genes,
oncolytic
viruses,
miRNA
presented,
well
strategies
can
improve
efficacy
glioblastoma,
such
CAR-T
cells,
nanoparticles,
exosomes.
Язык: Английский
Exploring miRNA therapies and gut microbiome–enhanced CAR-T cells: advancing frontiers in glioblastoma stem cell targeting
Naunyn-Schmiedeberg s Archives of Pharmacology,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 9, 2024
Язык: Английский
Transcriptional landscape of the interaction of human Mesenchymal Stem Cells with Glioblastoma in bioprinted co-cultures
Stem Cell Research & Therapy,
Год журнала:
2024,
Номер
15(1)
Опубликована: Ноя. 14, 2024
The
interaction
between
mesenchymal
stem
cells
(MSC)
and
Glioblastoma
(GBM),
although
potentially
of
the
highest
importance,
is
ill-understood.
This
due,
in
part,
to
lack
relevant
experimental
models.
similarity
vitro
situations
vivo
situation
can
be
improved
by
3D
co-culture
as
it
reproduces
key
cell–cell
interactions
tumor
microenvironment
(TME)
cancer
cells.
MSC
Can
acquired
characteristics
associated
fibroblasts
(CAF)
being
cultured
with
conditioned
medium
from
GBM
cultures
thus
are
called
MSCCAF.
We
co
Cultured
MSCCAF
patient
derived
a
scaffold
bioprinted
model.
studied
response
current
therapy
(e.g.
Temozolomide
+
/Radiation)
on
bulk
transcriptomic
(RNA
Seq)
epigenetic
(ATAC
analyses
modifications
induced
standard
treatment
scaffolds
mono-
or
co-cultures
±
analyzed.
found
that
mitochondrial
encoded
OXPHOS
genes
overexpressed
under
these
conditions
modified
both
(chemotherapy
radiation).
have
identified
two
new
markers
MSC/GBM
interactions,
one
epigenetically
regulated
(i.e.
TREM-1)
an
increased
overall
survival
patients
another
implicated
post-transcriptional
regulation
long
non-coding
RNA,
miR3681HG),
which
reduced
patients.
Язык: Английский